NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE171711 Query DataSets for GSE171711
Status Public on Apr 09, 2021
Title A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics
Organisms Homo sapiens; Mesocricetus auratus
Experiment type Expression profiling by high throughput sequencing
Summary The rapid repurposing of antivirals is particularly pressing during pandemics. However, rapid assays for assessing candidate drugs typically involve in vitro screens and cell lines that do not recapitulate human physiology at the tissue and organ levels. Here, we show that a microfluidic bronchial-airway-on-a-chip lined by highly differentiated human bronchial-airway epithelium and pulmonary endothelium can model viral infection, strain-dependent virulence, cytokine production, and the recruitment of circulating immune cells. In chips infected with pseudotyped SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), clinically relevant doses of the antimalarial drug amodiaquine inhibited infection, but clinical doses of hydroxychloroquine and other antiviral drugs that inhibit the entry of pseudotyped SARS-CoV-2 in cell lines under static conditions did not. We also show that amodiaquine showed substantial prophylactic and therapeutic activities in hamsters challenged with native SARS-CoV-2. The human airway-on-a-chip may accelerate the identification of therapeutics and prophylactics with repurposing potential.
 
Overall design Independent biological triplicates of transformed lung alveolar (A549) transduced with a vector expressing human ACE2 were pre-treated with amodiaquine (10 μM) for 1hr before SARS-CoV-2 infection (USA-WA1/2020, MOI: 0.1); 24hrs post infection samples were examined by mRNA-sequencing. Additionally, Syrian golden hamsters were treated with amodiaquine (75mg/kg) by oral gavage one day before SARS-CoV-2 infection (100 PFU), on the day of infection, and one and 2 days after infection. The animals were sacrificed and lungs harvested for mRNA-sequencing on day 3 post infection.
 
Contributor(s) tenOever BR, Blanco-Melo D
Citation(s) 33941899
Submission date Apr 08, 2021
Last update date Jul 09, 2021
Contact name Daniel Blanco Melo
Organization name Icahn School of Medicine at Mount Sina
Department Microbiology
Lab tenOever Lab
Street address One Gustave L. Levy Place, Box 1124
City New York
State/province NY
ZIP/Postal code 10029
Country USA
 
Platforms (2)
GPL18573 Illumina NextSeq 500 (Homo sapiens)
GPL24490 Illumina NextSeq 500 (Mesocricetus auratus)
Samples (9)
GSM5231210 Series1_A549-ACE2_Amodiaquine_CoV2-1
GSM5231211 Series1_A549-ACE2_Amodiaquine_CoV2-2
GSM5231212 Series1_A549-ACE2_Amodiaquine_CoV2-3
Relations
BioProject PRJNA720637
SRA SRP314026

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE171711_RawReadCounts_Hamster.tsv.gz 193.8 Kb (ftp)(http) TSV
GSE171711_RawReadCounts_Human.tsv.gz 173.9 Kb (ftp)(http) TSV
GSE171711_RawReadCounts_Virus.tsv.gz 186 b (ftp)(http) TSV
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap